Better Survival Seen With Spartalizumab Addition to Targeted Therapies in Melanoma Edited by Katie Lennon

https://www.medscape.com/viewarticle/better-survival-seen-spartalizumab-addition-targeted-2026a1000wnb?src= Greater overall survival (OS) was seen with spartalizumab added to dabrafenib and trametinib (sparta-DabTram) than with dabrafenib and trametinib alone in patients with BRAF V600-mutant metastatic melanoma in a trial. But the new phase 3 study failed to meet its primary endpoint of progression-free survival (PFS).